HDAC10
Polyamine deacetylase HDAC10
As of the edition of 20 October 2026, HDAC10 (polyamine deacetylase HDAC10, UniProt Q969S8) has 3 drugs tested at it and 5 companies on the list, 3 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q969S8
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Digestive system; Lungs and airways; Urinary and reproductive; Pregnancy and women's health
- Registered trials of its drugs
- 225
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Went quiet | 1 |
| Stopped | 1 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Tucidinostat | Marketed | Phase 4 | none listed |
| Pracinostat | Went quiet | Phase 3 | none listed |
| MTX110 | Stopped | Phase 1 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Engaged | 1 |
| Undetermined | 1 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Helsinn Healthcare | Route A |
| Biodexa Pharmaceuticals | Route A |
| S*Bio | Route A |
The other 2 companies at HDAC10
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at HDAC10, ranked, with the facts behind eachRequest access. Nothing is shown until you do.